

संख्या / F. No. 8(34)/2014/Div. II/NPPA  
भारत सरकार  
Government of India  
रसायन और उर्वरक मंत्रालय  
Ministry of Chemicals & Fertilizers  
औषध विभाग  
Department of Pharmaceuticals  
राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण  
National Pharmaceutical Pricing Authority

तीसरी/पांचवी मंजिल 5<sup>th</sup> / 3<sup>rd</sup> Floor,  
वाई.एम.सी.ए. सांस्कृतिक केन्द्र बिल्डिंग  
YMCA Cultural Center Building,  
1, जय सिंह रोड, नई दिल्ली-110001  
1, Jai Singh Road, N. Delhi – 110001.  
दिनांक : 07.2.2017

**OFFICE MEMORANDUM**

**Subject: Revised guidelines for representation - display of draft version of proposed price Calculation Sheets for proposed revised/notified ceiling price/retail price on NPPA's website-**

The undersigned is directed to refer to OMs of even no. dated 13.7.2016, 10.10.2016 & OM F. No. 20(1)/2014/Div. III/NPPA dated 01.02.2017. The NPPA at its 172<sup>nd</sup> overall and 40<sup>th</sup> Authority meeting under DPCO, 2013, decided that in the interest of expedited price fixation of essential drugs (scheduled medicines) cases in public interest, pharmaceutical companies submitting representation against draft proposed calculation sheets (prior to notification) of ceiling/retail price shall submit following supporting documents/information relating to Price to Retailer (PTR) and Moving Annual Turnover (MAT) data for the month of **August, 2015 duly attested with name, designation, mobile no., signature & seal of the authorized officer of the company.**

- (i) copies of sample invoices to retailer,
- (ii) samples/ self attested copies of samples,
- (iii) summary of all the invoices issued [giving details like Invoice No., Date, Name of Distributor & Retailer, Quantity, Pack Size, PTR (excluding VAT), Discounts/Free Goods, (if any)] for the month of August, 2015 and
- (iv) copies of supporting IPDMS submission alongwith the certificate to the effect that they have filed all the requisite forms for all their formulations online through Integrated Pharmaceutical DataBase Management System (IPDMS) with NPPA,

2. Companies which have already submitted representations are required to supplement their status through IPDMS by fax/e-mail (i.e. nppa@nic.in) **positively by**

February 10, 2017 and inform accordingly, failing which such representations will not be considered and are liable to be rejected outrightly.

3. In case where representation is made on the basis of discontinuation of any brand/ pack size etc, the burden of proving this contention 'with verifiable documentary evidence' lies with the pharmaceuticals company.

4. All the drug manufacturing/marketing companies are directed to comply with these instructions in entirety in order to ensure that their representations are properly considered.



(ए. के. खुराना)  
निदेशक

Copy to: All Apex Pharma organizations/Associations i.e. OPPI, IDMA, AISSPMA, PICCI, CII, IPA and FOPE for necessary action please.